Contents

Highlights of This Issue 321

SPECIAL FEATURES

CCR Translations

323

BAP1tism of a Tumor Suppressor
Scott E. Woodman
See article p. 408

BAP1tism of a Tumor Suppressor
Scott E. Woodman
See article p. 408

Molecular Pathways

326

Molecular Pathways:
Osteoclast-Dependent and
Osteoclast-Independent Roles of the
RANKL/RANK/OPG Pathway in
Tumorigenesis and Metastasis
William C. Dougall

New Challenges in Endpoints for Drug
Development in Advanced Melanoma
Antoni Ribas, Peter Hersey, Mark R. Middleton,
Helen Gogas, Keith T. Flaherty,
Vernon K. Sondak, and John M. Kirkwood

Perspective

336

New Challenges in Endpoints for Drug
Development in Advanced Melanoma
Antoni Ribas, Peter Hersey, Mark R. Middleton,
Helen Gogas, Keith T. Flaherty,
Vernon K. Sondak, and John M. Kirkwood

Review

342

Multiple Myeloma Mesenchymal Stem
Cells: Characterization, Origin, and
Tumor-Promoting Effects
Michaela R. Reagan and Irene M. Ghobrial

HUMAN CANCER BIOLOGY

350

Molecular Analysis of Colorectal
Tumors within a Diverse Patient
Cohort at a Single Institution
Brooke E. Sylvester, Dezhegng Huo,
Andrey Khramtsov, Jing Zhang,
Rana V. Smalling, Sope Olugbile, Blase N. Polite,
and Olufunmilayo I. Olopade

A Noncanonical Flt3ITD/NF-κB
Signaling Pathway Represses DAPK1
in Acute Myeloid Leukemia
Rajasubramaniam Shanmugam, Padmaja Gade,
Anique Wilson-Weekes, Hamid Sayar,
Attaya Suvannasankha, Chirayu Goswami,
Lang Li, Sushil Gupta, Angelo A. Cardoso,
Tareq Al Baghdadi, Katie J. Sargent,
Larry D. Cripe, Dhananjaya V. Kalvakolanu, and
H. Scott Boswell

Punctate LC3B Expression Is a
Common Feature of Solid Tumors and
Associated with Proliferation,
Metastasis, and Poor Outcome
Rossitza Lazova, Robert L. Camp,
Vincent Klump, Summar F. Siddiqui,
Ravi K. Amaravadi, and John M. Pawelek

Ran Is a Potential Therapeutic Target
for Cancer Cells with Molecular
Changes Associated with Activation
of the PI3K/Akt/mTORC1 and
Ras/MEK/ERK Pathways
Hui-Fung Yuen, Ka-Kui Chan, Claire Grills,
James T. Murray, Angela Platt-Higgins,
Osama Sharaf Eldin, Ken O’Byrne, Pasi Janne,
Dean A. Fennell, Patrick G. Johnston,
Philip S. Rudland, and Mohamed El-Tanani

Serum Interleukin-6, Insulin, and
HOMA-IR in Male Individuals with
Colorectal Adenoma
Yu Sasaki, Hiroaki Takeda, Takeshi Sato,
Tomohiko Orii, Shoichi Nishise, Ko Naqino,
Daisuke Iwano, Takao Yaotla,
Kazuya Yoshizawa, Hideki Saito,
Yasuhiisa Tanaka, and Sumio Kawata

Lifetime Cancer Risks in Individuals
with Germline PTEN Mutations
Min-Han Tan, Jessica L. Mester, Joanne Ngeow,
Lisa A. Rybicki, Mohammed S. Orloff, and
Charis Eng

CANCER THERAPY: PRECLINICAL

408

Histone Deacetylase Inhibitors Induce
Growth Arrest and Differentiation in
Uveal Melanoma
Solange Landreville, Olga A. Agapova,
Katie A. Matatall, Zachary T. Kneass,
Michael D. Onken, Ryan S. Lee,
Anne M. Bowcock, and J. William Harbour

See commentary p. 323

417

Leflunomide Induces Apoptosis in
Fludarabine-Resistant and Clinically
Refractory CLL Cells
Sascha Dietrich, Oliver H. Krämer, Esther Hahn,
Claudia Schäfer, Thomas Giese, Michael Hess,
Theresa Tretter, Michael Rieger,
Jennifer Hüllein, Thorsten Zenz, Anthony D. Ho,
Peter Dregger, and Thomas Luft

The Journal of Clinical and Translational Research

January 15, 2012 • Volume 18 • Number 2

www.aacrjournals.org
Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma


Bexarotene via CBP/p300 Induces Suppression of NF-κB–Dependent Cell Growth and Invasion in Thyroid Cancer

Audrey Cras, Beatrice Politis, Nicole Balitrand, Diane Darsin-Bettinger, Pierre Yves Boelle, Bruno Cassinat, Marie-Elisabeth Toubert, and Christine Chomienne

Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth

Andreas Wicki, Christoph Buchlitz, Annette Orleth, Reto Ritschard, Inke Albrecht, Richard Herrmann, Gerhard Christofori, and Christoph Mamot

EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells

Michele Cioffi, Jorge Dorado, Patrick A. Raueterle, and Christopher Heeschen

CPTH6, a Thiazole Derivative, Induces Histone Hypoaetylation and Apoptosis in Human Leukemia Cells

Daniela Trisciuglio, Ylenia Ragazzoni, Andrea Pelosi, Marrianna Desideri, Simone Carradori, Chiara Gabellini, Giovanna Maresca, Riccardo Nescattelli, Daniela Secchi, Adriana Bolasco, Bruna Bizzarri, Chiara Cavaliere, Igea D’Agnano, Patrizia Filetici, Lucia Ricci-Vitiani, Maria Giulia Rizzo, and Donatella Del Bufalo

Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia


VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC

Hailing Lu, Gregory N. Dietsch, Mauria-Ann H. Matthews, Yi Yang, Smita Ghanekar, Margaret Inokuma, Maria Suni, Vernon C. Maino, Katherine E. Henderson, James Jeffry Howbert, and Robert M. Herschberg

Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor


Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer

Jhi-Hsiang Lee, Elisa Giovannetti, Jin-Hyeok Hwang, Iacopo Petrini, Quyan Wang, Johannes Voortman, Yonghong Wang, Seth M. Steinberg, Niccola Funel, Paul S. Meltzer, Yisong Wang, and Giuseppe Giaccone

MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma


Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas

Harry H. Yoon, Qian Shi, William R. Sukov, Anne E. Wiktor, Maliba Khan, Christopher A. Sattler, Axel Grotthey, Tsung-Teh Wu, Robert B. Diasio, Robert B. Jenkins, and Frank A. Sinicrope

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

John M. Kirkwood, Lars Bastholt, Caroline Robert, Jeff Sosman, James Larkin, Peter Hersey, Mark Middleton, Mireille Cantarini, Victoria Zazulina, Karin Kemsley, and Reinhard Dummer
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty, Patricia M. LoRusso, Angela DeMichele, Vandana G. Abramson, Rachel Courtney, Sophia S. Randolph, M. Naveed Shaik, Keith D. Wilner, Peter J. O’Dwyer, and Gary K. Schwartz

A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303

Genetic Variations in Epigenetic Genes Are Predictors of Recurrence in Stage I or II Non–Small Cell Lung Cancer Patients
Klaus W. Wagner, Yuanqing Ye, Jie Lin, Ara A. Vaporciyan, Jack A. Roth, and Xifeng Wu

ABOUT THE COVER

Although antiangiogenic therapies are effective and comparatively safe treatments against human cancer, renal toxicity is one of the major concerns. Anti-VEGFR2 immunoliposomes loaded with a chemotherapeutic drug showed marked antitumor activity in various tumor models. Importantly, no long-term renal side effects were evident with this therapy. This image shows a section of mouse kidneys 18 months after repeated injection of anti-VEGFR2 immunoliposomes loaded with doxorubicin. For details, see the article by Wicki and colleagues on page 454 of this issue.